Anavex life sciences to present at the 23rd annual needham virtual healthcare conference

New york, march 25, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome, schizophrenia and other central nervous system (cns) diseases, today announced that it will present at the 23rd annual needham virtual healthcare conference, april 8 – 11, 2024. christopher u missling, phd, president & chief executive officer will present the company scheduled at 8:45 am (et) on monday, april 8th, 2024.
AVXL Ratings Summary
AVXL Quant Ranking